Physician
Spectrum Pain Clinics INC.
Spectrum Pain Clinics INC. was paid $1.32M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 47% of everything it billed.
33Billing provider infoSPECTRUM PAIN CLINICS INC.
CORDOVA, TN 38016
CORDOVA, TN 38016
33aNPI1265533897assigned 09/26/2006
33bProvider typeAdult Medicine Physician
28Total paid$1.32M
24GClaims210,370
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Medicine Physician providers in Tennessee
Rank by total paid#1 of 15
Median peer was paid$40K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,642 | $28K | |
| 2019 | 29,456 | $178K | |
| 2020 | 72,959 | $223K | |
| 2021 | 31,743 | $246K | |
| 2022 | 27,377 | $217K | |
| 2023 | 22,696 | $197K | |
| 2024incomplete | 21,497 | $230K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 47% | 40,782 | 30,322 | $614K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 15,531 | 11,844 | $153K |
| 62323 | 6.3% | 2,196 | 1,301 | $84K | |
| 64635 | 4.7% | 1,277 | 675 | $62K | |
| 64493 | 4.6% | 2,117 | 1,013 | $60K | |
| 64636 | 3.6% | 1,687 | 673 | $47K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 11,884 | 7,500 | $35K |
| 96130 | 2.6% | 4,585 | 3,444 | $34K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.3% | 8,361 | 4,850 | $30K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 2.1% | 3,920 | 1,130 | $28K |
| 99152 | 1.8% | 3,585 | 1,676 | $24K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.7% | 608 | 484 | $23K |
62 more codes
| 64494 | 1.5% | 2,112 | $19K | |
| 64495 | 1.1% | 1,857 | $15K | |
| 20611 | <1% | 1,007 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 514 | $11K |
| 96138 | <1% | 4,981 | $10K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,526 | $9K |
| 27096 | <1% | 182 | $9K | |
| 20610 | <1% | 427 | $6K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,730 | $6K |
| 77002 | <1% | 430 | $5K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,727 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 479 | $4K |
| 99406 | <1% | 1,572 | $3K | |
| 80305 | <1% | 1,450 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 464 | $3K |
| J3490 | Unclassified drugs | <1% | 701 | $974.53 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 102 | $710.83 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,227 | $667.61 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 252 | $607.78 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 90 | $338.70 |
| 76942 | <1% | 27 | $303.68 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 90 | $176.62 |
| 99156 | <1% | 34 | $109.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 483 | $87.70 |
| 99157 | <1% | 34 | $83.00 | |
| 64490 | <1% | 25 | $63.17 | |
| 64491 | <1% | 25 | $31.36 | |
| G9717 | Documentation stating the patient has had a diagnosis of bipolar disorder | <1% | 2,299 | $16.67 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 61 | $3.83 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 18,332 | $0.23 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 12,796 | $0.06 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 7,772 | $0.04 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | <1% | 9,131 | $0.04 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 1,375 | $0.02 |
| G8482 | Influenza immunization administered or previously received | <1% | 740 | $0.01 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 796 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 3,142 | $0.00 |
| 1101F | 0% | 1,017 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 3,865 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 1,132 | $0.00 |
| G9908 | Patient identified as tobacco user did not receive tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 435 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 392 | $0.00 |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 2,643 | $0.00 |
| 1036F | 0% | 1,915 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 1,177 | $0.00 |
| J1094 | Injection, dexamethasone acetate, 1 mg | 0% | 134 | $0.00 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 40 | $0.00 |
| 1111F | 0% | 99 | $0.00 | |
| 1123F | 0% | 42 | $0.00 | |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 8,145 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 2,128 | $0.00 |
| 3288F | 0% | 939 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 731 | $0.00 |
| G8511 | Screening for depression documented as positive, follow-up plan not documented, reason not given | 0% | 33 | $0.00 |
| 4004F | 0% | 522 | $0.00 | |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 636 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 875 | $0.00 |
| 1124F | 0% | 249 | $0.00 | |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 158 | $0.00 |
| 4040F | 0% | 300 | $0.00 | |
| G9500 | Radiation exposure indices documented in final report for procedure using fluoroscopy | 0% | 192 | $0.00 |
| G8785 | Blood pressure reading not documented, reason not given | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHALL, JEFFREY (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Coastal Oral and Maxillofacial Surgery, PC | North Charleston, SC | $6K |
| Encore Surgical Institute LLC | Cordova, TN | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.